Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105
- 6 July 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 5 (2) , 114-121
Abstract
The health-related quality of life (HRQL) and fatigue of brain cancer survivors treated with donepezil or placebo for cognitive symptoms after radiation therapy were examined. One hundred ninety-eight patients who completed >30 Gy fractionated whole or partial brain irradiation at least 6 months prior to enrollment were randomized to either placebo or donepezil (5 mg for 6 weeks followed by 10 mg for 18 weeks) in a phase 3 trial. A neurocognitive battery, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue, was administered at baseline, 12 weeks, and 24 weeks. At 12 weeks, donepezil resulted in improvements in only emotional functioning (P = .04), with no significant effects at week 24. Associations by level of baseline cognitive symptoms (above or below the median score of the baseline FACT-Br “additional concerns/brain” subscale), indicated that participants with more baseline symptoms who received donepezil versus placebo, showed improvements in social (P = .02) and emotional well-being (P = .038), other concerns/brain (P = .003) and the FACT-Br total score (P = .004) at 12 weeks, but not 24 weeks. However, participants with fewer baseline symptoms randomized to donepezil versus placebo reported lower functional well-being at both 12 (P = .015) and 24 weeks (P = .009), and greater fatigue (P = .02) at 24 weeks. The positive impact of donepezil on HRQL was greater in survivors reporting more baseline cognitive symptoms. Donepezil had significantly worse effects on fatigue and functional well-being among participants with fewer baseline symptoms. Future interventions with donepezil should target participants with more baseline cognitive complaints to achieve greater therapeutic impact and lessen potential side effects of treatment.Keywords
Funding Information
- National Institutes of Health
- National Institute of Nursing Research
This publication has 41 references indexed in Scilit:
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Distress and quality of life in primary high-grade brain tumor patientsSupportive Care in Cancer, 2009
- Donepezil for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2007
- Gender difference in relation to depression and quality of life among patients with a primary brain tumorEuropean Psychiatry, 2006
- Donepezil for dementia due to Alzheimer's diseaseCochrane Database of Systematic Reviews, 2006
- Prospective Study of Quality of Life in Adults with Newly Diagnosed High-grade GliomasJournal of Neuro-Oncology, 2005
- Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's diseaseInternational Journal of Geriatric Psychiatry, 2004
- The PHQ-9Journal of General Internal Medicine, 2001
- Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJournal of Pain and Symptom Management, 1997
- The hopkins verbal learning test: Development of a new memory test with six equivalent formsThe Clinical Neuropsychologist, 1991